JP2007509985A - カプサイシン受容体作動薬 - Google Patents

カプサイシン受容体作動薬 Download PDF

Info

Publication number
JP2007509985A
JP2007509985A JP2006538401A JP2006538401A JP2007509985A JP 2007509985 A JP2007509985 A JP 2007509985A JP 2006538401 A JP2006538401 A JP 2006538401A JP 2006538401 A JP2006538401 A JP 2006538401A JP 2007509985 A JP2007509985 A JP 2007509985A
Authority
JP
Japan
Prior art keywords
compound
amine
alkyl
trifluoromethyl
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006538401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509985A5 (enExample
Inventor
バクサヴァッチャラム ラージャゴーパール
エイ ブルム チャールズ
ブリールマン ハリー
エム コールドウェル ティモシー
エヌ コートライト ダニエル
ジェイ ホジェッツ ケヴィン
エム ピーターソン ジョン
ジェン ジャオジャン
Original Assignee
ニューロジェン・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロジェン・コーポレーション filed Critical ニューロジェン・コーポレーション
Publication of JP2007509985A publication Critical patent/JP2007509985A/ja
Publication of JP2007509985A5 publication Critical patent/JP2007509985A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
JP2006538401A 2003-10-31 2004-10-28 カプサイシン受容体作動薬 Withdrawn JP2007509985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51624603P 2003-10-31 2003-10-31
PCT/US2004/036295 WO2005042498A2 (en) 2003-10-31 2004-10-28 4-amino (aza) quinoline derivatives as capsaicin receptor agonists

Publications (2)

Publication Number Publication Date
JP2007509985A true JP2007509985A (ja) 2007-04-19
JP2007509985A5 JP2007509985A5 (enExample) 2007-12-13

Family

ID=34549510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538401A Withdrawn JP2007509985A (ja) 2003-10-31 2004-10-28 カプサイシン受容体作動薬

Country Status (7)

Country Link
US (1) US20060194805A1 (enExample)
EP (1) EP1678149A2 (enExample)
JP (1) JP2007509985A (enExample)
CN (1) CN1890223A (enExample)
AU (1) AU2004285052A1 (enExample)
CA (1) CA2540342A1 (enExample)
WO (1) WO2005042498A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508487A (ja) * 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
JP2022529739A (ja) * 2019-04-24 2022-06-23 チルドレンズ メディカル センター コーポレイション Ｐａｐｄ５阻害剤およびその使用方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055003A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
CN1964717A (zh) * 2004-04-08 2007-05-16 神经能质公司 经取代∴啉－4－基胺
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US9757476B2 (en) * 2006-06-08 2017-09-12 Warsaw Orthopedic, Inc. Compositions and methods for diagnosis of axial pain with or without radiculopathy
CN101479269A (zh) * 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
US7943666B2 (en) * 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
JP2010501593A (ja) * 2006-08-24 2010-01-21 セレネックス， インコーポレイテッド イソキノリン、キナゾリンおよびフタラジン誘導体
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
KR101503286B1 (ko) * 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 ｔｒｐｖ1 저해제
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
MX2010006457A (es) * 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
JP5728234B2 (ja) * 2008-02-15 2015-06-03 ボーン・セラピューティクス 骨関節疾患の治療又は予防において使用するための医薬組成物
BRPI0905369C8 (pt) 2008-02-15 2021-05-25 Bone Therapeutics composição farmacêutica, uso da composição farmacêutica e kit compartimentado
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
US9216171B2 (en) * 2009-05-07 2015-12-22 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation
CN102811620B (zh) 2010-01-25 2015-03-25 Chdi基金会股份有限公司 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012060845A1 (en) * 2010-11-05 2012-05-10 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation
CN102091061B (zh) * 2010-11-12 2012-07-04 河北医科大学 1,2-二苯乙烯衍生物在制药中的应用
US9051318B2 (en) 2011-03-09 2015-06-09 Merck Patent Gmbh Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10092528B2 (en) 2013-03-13 2018-10-09 Altria Client Services Llc Application of encapsulated capsaicin and analogues thereof for controlling calorie intake
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN107427506A (zh) 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
US11066420B2 (en) * 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
EP3735408B1 (en) 2018-01-05 2023-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivatives, method of preparation and applications thereof
CN111393380A (zh) * 2018-07-09 2020-07-10 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂
AU2022380831A1 (en) * 2021-11-05 2024-06-06 Chinese University Of Hong Kong, Shenzhen Alpha-2a adrenergic receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
JP2003509497A (ja) * 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン化合物とそれらを含有する医薬組成物
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
NZ522696A (en) * 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
CN1627944A (zh) * 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508487A (ja) * 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
JP2022529739A (ja) * 2019-04-24 2022-06-23 チルドレンズ メディカル センター コーポレイション Ｐａｐｄ５阻害剤およびその使用方法
JP7617020B2 (ja) 2019-04-24 2025-01-17 チルドレンズ メディカル センター コーポレイション Ｐａｐｄ５阻害剤およびその使用方法
US12486234B2 (en) 2019-04-24 2025-12-02 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US20060194805A1 (en) 2006-08-31
CN1890223A (zh) 2007-01-03
AU2004285052A1 (en) 2005-05-12
WO2005042498A3 (en) 2005-07-07
WO2005042498A2 (en) 2005-05-12
EP1678149A2 (en) 2006-07-12
CA2540342A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
JP2006528640A (ja) 置換ピリジン−２−イルアミン類縁体
JP2006515847A (ja) カプサイシン受容体調節剤としてのカルボン酸、ホスフェート又はホスホネート置換キナゾリン−４−イルアミン類縁体
JP2007523867A (ja) 置換複素環式ジアリールアミン類縁体
JP2008528506A (ja) ヘテロアリール置換ピペラジニル−ピリジン類縁体
US20060194805A1 (en) Capsaicin receptor agonists
JP2007520444A (ja) 置換二環式キナゾリン−４−イルアミン誘導体
JP2011137018A (ja) 置換キノリン−４−イルアミン類縁体
JP5421108B2 (ja) ２−フェノキシピリミジノン類縁体
JP4955554B2 (ja) 置換ビアリールピペラジニル−ピリジン類縁体
JP2007534624A (ja) ビアリールピペラジニル−ピリジン類縁体
JP2007523875A (ja) バニロイド受容体リガンドとしての置換ピリミジン−４−イルアミン類縁体
JP2010501571A (ja) ハロアルキル−置換ピリミジノン誘導体
JP2008526997A (ja) ヘテロアリール置換キノリン−４−イルアミン類縁体
JP2007532570A (ja) 置換シンノリン−４−イルアミン類
US7329664B2 (en) Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
JP2008528613A (ja) 置換ピリダジニル−及びピリミジニル−キノリン−４−イルアミン類縁体
JP2010509224A (ja) ｃｉｓ−シクロヘキシル置換ピリミジノン誘導体
JP2007526339A (ja) アリール置換プリン類縁体
JP2007526323A (ja) アリールアルキルアミノ置換キナゾリン類縁体
JP2008515988A (ja) 置換ビアリールキノリン−４−イルアミン類縁体
JP2007526332A (ja) ヘテロアルキル置換ビフェニル−４−カルボン酸アリールアミド類縁体
JP2008523156A (ja) 置換ビアリール類縁体
JP2008523152A (ja) ピペラジニル−ピリジン類縁体
JP2007528419A (ja) 置換５，１２−ジアザ−ベンゾアントラセン類縁体
JP2007537978A (ja) アリール基で置換されたベンゾ［ｄ」イソチアゾール−３−イルアミン類縁体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071029

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090713